Evidence map›Paper›PMID 27496775›Full record

ArticleApplied and environmental microbiology2016

Extending CRISPR-Cas9 Technology from Genome Editing to Transcriptional Engineering in the Genus Clostridium.

Mark R Bruder, Michael E Pyne, Murray Moo-Young, Duane A Chung, C Perry Chou

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Applied and environmental microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. CRISPR-Based Gene Editing inPharmaceuticals (Basel, Switzerland) · 2023
    Review
  6. Single and multiplexed gene repression in solventogenicSynthetic and systems biotechnology · 2023
    Article
  7. A fluorescent reporter system for anaerobic thermophiles.Frontiers in bioengineering and biotechnology · 2023
    Article
  8. Tuning of Gene Expression inACS synthetic biology · 2022
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Metabolic Engineering of Histidine Kinases inFrontiers in bioengineering and biotechnology · 2020
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mark R BruderDepartment of Chemical Engineering, University of Waterloo, Waterloo, Ontario, Canada.
Michael E PyneDepartment of Chemical Engineering, University of Waterloo, Waterloo, Ontario, Canada.
Murray Moo-YoungDepartment of Chemical Engineering, University of Waterloo, Waterloo, Ontario, Canada.
Duane A ChungDepartment of Chemical Engineering, University of Waterloo, Waterloo, Ontario, Canada Algaeneers Inc., Hamilton, Ontario, Canada Neemo Inc., Hamilton, Ontario, Canada duane.chung@uwaterloo.ca cpchou@uwaterloo.ca.
C Perry ChouDepartment of Chemical Engineering, University of Waterloo, Waterloo, Ontario, Canada duane.chung@uwaterloo.ca cpchou@uwaterloo.ca.
University of Waterloo · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery and exploitation of the prokaryotic adaptive immunity system based on clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) proteins have revolutionized genetic engineering. CRISPR-Cas tools have enabled extensive genome editing as well as efficient modulation of the transcriptional program in a multitude of organisms. Progress in the development of genetic engineering tools for the genus Clostridium has lagged behind that of many other prokaryotes, presenting the CRISPR-Cas technology an opportunity to resolve a long-existing issue. Here, we applied the Streptococcus pyogenes type II CRISPR-Cas9 (SpCRISPR-Cas9) system for genome editing in Clostridium acetobutylicum DSM792. We further explored the utility of the SpCRISPR-Cas9 machinery for gene-specific transcriptional repression. For proof-of-concept demonstration, a plasmid-encoded fluorescent protein gene was used for transcriptional repression in C. acetobutylicum Subsequently, we targeted the carbon catabolite repression (CCR) system of C. acetobutylicum through transcriptional repression of the hprK gene encoding HPr kinase/phosphorylase, leading to the coutilization of glucose and xylose, which are two abundant carbon sources from lignocellulosic feedstocks. Similar approaches based on SpCRISPR-Cas9 for genome editing and transcriptional repression were also demonstrated in Clostridium pasteurianum ATCC 6013. As such, this work lays a foundation for the derivation of clostridial strains for industrial purposes. IMPORTANCE: After recognizing the industrial potential of Clostridium for decades, methods for the genetic manipulation of these anaerobic bacteria are still underdeveloped. This study reports the implementation of CRISPR-Cas technology for genome editing and transcriptional regulation in Clostridium acetobutylicum, which is arguably the most common industrial clostridial strain. The developed genetic tools enable simpler, more reliable, and more extensive derivation of C. acetobutylicum mutant strains for industrial purposes. Similar approaches were also demonstrated in Clostridium pasteurianum, another clostridial strain that is capable of utilizing glycerol as the carbon source for butanol fermentation, and therefore can be arguably applied in other clostridial strains.

Indexed as

CRISPR-Cas SystemsBacterial ProteinsClostridium acetobutylicumClustered Regularly Interspaced Short Palindromic RepeatsGene EditingGenetic EngineeringGenome, BacterialTranscription, GeneticBacterial Proteins

Identifiers

PMID27496775
PMCPMC5068152
OpenAlexW2479285410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.